Evidence map›Paper›PMID 40217754›Full record

ArticleJournal of clinical medicine2025

The PD1 Molecule May Contribute to Lower Treatment-Free Remission Rates in Patients with Chronic Myeloid Leukemia with the e13a2 Transcript.

Paulina Kwaśnik, Michał Kiełbus, Joanna Zaleska, Dorota Link-Lenczowska, Magdalena Zawada, Hubert Wysogląd, Tomasz Sacha, Krzysztof Giannopoulos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paulina KwaśnikDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0002-4244-1213
Michał KiełbusDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0001-6156-6217
Joanna ZaleskaDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0002-4417-7831
Dorota Link-LenczowskaDiagnostic Department of Hematology and Genetics, The University Hospital in Kraków, 30-688 Kraków, Poland.
Magdalena ZawadaDiagnostic Department of Hematology and Genetics, The University Hospital in Kraków, 30-688 Kraków, Poland.ORCID 0000-0001-9105-1767
Hubert WysoglądDepartment of Hematology, University Hospital in Kraków, 30-688 Kraków, Poland.
Tomasz SachaDepartment of Hematology, University Hospital in Kraków, 30-688 Kraków, Poland.
Krzysztof GiannopoulosDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0003-0135-4030

Funding

Medical University of Lublin DS 462National Science Center 2018/31/B/NZ6/03361
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chronic myeloid leukemiaimatinib withdrawalimmune biomarkertranscript typetreatment-free remission

Identifiers

PMID40217754
PMCPMC11989261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.